EDITAS MEDICINE, INC. Proceeds from Sale and Maturity of Marketable Securities
EDITAS MEDICINE, INC. (EDIT) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-05
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $40.01M, a 53.96% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $139.01M, a 45.95% decline from fiscal 2024.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $257.19M, a 0.89% decline from fiscal 2023.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $259.50M, a 40.12% decline from fiscal 2022.
- EDITAS MEDICINE, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $433.35M, a 19.58% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $40.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $40.01M derived: sum of 3 quarters · filed 2026-05-05 | $82.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $40.01M derived: sum of 2 quarters · filed 2026-03-09 | $82.50M derived: sum of 3 quarters · filed 2026-08-05 | $139.01M 10-K · filed 2026-03-09 |
| 2025-09-30 | $40.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $82.50M derived: sum of 2 quarters · filed 2026-08-05 | $139.01M 10-Q · filed 2025-11-10 | $170.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $42.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $99.00M 10-Q · filed 2026-08-05 | $130.49M derived: sum of 3 quarters · filed 2026-08-05 | $217.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $56.50M 10-Q · filed 2026-05-05 | $88.00M derived: sum of 2 quarters · filed 2026-05-05 | $174.90M derived: sum of 3 quarters · filed 2026-05-05 | $230.34M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $31.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $118.39M derived: sum of 2 quarters · filed 2026-03-09 | $173.84M derived: sum of 3 quarters · filed 2026-03-09 | $257.19M 10-K · filed 2026-03-09 |
| 2024-09-30 | $86.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $142.34M derived: sum of 2 quarters · filed 2025-11-10 | $225.69M 10-Q · filed 2025-11-10 | $328.60M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $55.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $138.79M 10-Q · filed 2025-08-12 | $241.69M derived: sum of 3 quarters · filed 2025-08-12 | $290.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $83.35M 10-Q · filed 2025-05-12 | $186.25M derived: sum of 2 quarters · filed 2025-05-12 | $235.25M derived: sum of 3 quarters · filed 2025-05-12 | $276.95M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $102.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $151.90M derived: sum of 2 quarters · filed 2025-03-05 | $193.60M derived: sum of 3 quarters · filed 2025-03-05 | $259.50M 10-K · filed 2025-03-05 |
| 2023-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $90.70M derived: sum of 2 quarters · filed 2024-11-04 | $156.60M 10-Q · filed 2024-11-04 | $235.10M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $41.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $107.61M 10-Q · filed 2024-08-07 | $186.10M derived: sum of 3 quarters · filed 2025-03-05 | $302.21M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $65.91M 10-Q · filed 2024-05-08 | $144.41M derived: sum of 2 quarters · filed 2025-03-05 | $260.51M derived: sum of 3 quarters · filed 2025-03-05 | $380.26M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $78.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $194.60M derived: sum of 2 quarters · filed 2025-03-05 | $314.35M derived: sum of 3 quarters · filed 2025-03-05 | $433.35M 10-K · filed 2025-03-05 |
| 2022-09-30 | $116.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $235.85M derived: sum of 2 quarters · filed 2023-11-03 | $354.85M 10-Q · filed 2023-11-03 | $439.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $119.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $238.75M 10-Q · filed 2023-08-02 | $323.08M derived: sum of 3 quarters · filed 2024-02-28 | $396.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $119.00M 10-Q · filed 2023-05-05 | $203.33M derived: sum of 2 quarters · filed 2024-02-28 | $276.45M derived: sum of 3 quarters · filed 2024-02-28 | $350.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $84.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $157.45M derived: sum of 2 quarters · filed 2024-02-28 | $231.65M derived: sum of 3 quarters · filed 2024-02-28 | $362.40M 10-K · filed 2024-02-28 |
| 2021-09-30 | $73.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $147.33M derived: sum of 2 quarters · filed 2022-11-02 | $278.08M 10-Q · filed 2022-11-02 | $308.58M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $74.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $204.95M 10-Q · filed 2022-08-03 | $235.45M derived: sum of 3 quarters · filed 2023-02-22 | $318.95M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $130.75M 10-Q · filed 2022-05-04 | $161.25M derived: sum of 2 quarters · filed 2023-02-22 | $244.75M derived: sum of 3 quarters · filed 2023-02-22 | $320.75M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $30.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $114.00M derived: sum of 2 quarters · filed 2023-02-22 | $190.00M derived: sum of 3 quarters · filed 2023-02-22 | $305.00M 10-K · filed 2023-02-22 |
| 2020-09-30 | $83.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $159.50M derived: sum of 2 quarters · filed 2021-11-09 | $274.50M 10-Q · filed 2021-11-09 | $321.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $191.00M 10-Q · filed 2021-08-05 | $237.50M derived: sum of 3 quarters · filed 2022-02-24 | $316.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $115.00M 10-Q · filed 2021-05-06 | $161.50M derived: sum of 2 quarters · filed 2022-02-24 | $240.00M derived: sum of 3 quarters · filed 2022-02-24 | $349.50M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $46.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $125.00M derived: sum of 2 quarters · filed 2022-02-24 | $234.50M derived: sum of 3 quarters · filed 2022-02-24 | $360.50M 10-K · filed 2022-02-24 |
| 2019-09-30 | $78.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $188.00M derived: sum of 2 quarters · filed 2020-11-06 | $314.00M 10-Q · filed 2020-11-06 | $415.00M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $109.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $235.50M 10-Q · filed 2020-08-07 | $336.50M derived: sum of 3 quarters · filed 2021-02-26 | $450.50M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $126.00M 10-Q · filed 2020-05-08 | $227.00M derived: sum of 2 quarters · filed 2021-02-26 | $341.00M derived: sum of 3 quarters · filed 2021-02-26 | $442.50M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $101.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $215.00M derived: sum of 2 quarters · filed 2021-02-26 | $316.50M derived: sum of 3 quarters · filed 2021-02-26 | $411.00M 10-K · filed 2021-02-26 |
| 2018-09-30 | $114.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $215.50M derived: sum of 2 quarters · filed 2019-11-12 | $310.00M 10-Q · filed 2019-11-12 | $414.00M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $101.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $196.00M 10-Q · filed 2019-08-07 | $300.00M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2018-03-31 | $94.50M 10-Q · filed 2019-05-08 | $198.50M derived: sum of 2 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $104.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $193.50M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $89.50M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |